Journal of Cosmetic Dermatology

DefenAge® Skincare Announces Defensin Master Anti-Aging Patent for Signature Cell Stimulating Technology

Retrieved on: 
Friday, November 25, 2022
Black Friday, Student, Journal, Sale, Skin, Journal of Cosmetic Dermatology, Cell, MMHC, Epidermis, Animal, Patent, Irritation, Scalp, Multimedia, Ageing, BOGO, MPH, Woman, Inflammation, Face, Wound healing, Monarch School, Montana, Regenerative medicine, Human, United States patent law, Pigment, Heart, Pharmaceutical industry, Cosmetics, Defensin, Dermatology, MD

CARLSBAD, Calif., Nov. 25, 2022 /PRNewswire/ -- DefenAge® Skincare, manufacturer and distributor of revolutionary, evidence-based, anti-aging products, announces the new Defensin Master Anti-Aging Patent issued by the US Patent Office (Patent #11,491,096).

Key Points: 
  • CARLSBAD, Calif., Nov. 25, 2022 /PRNewswire/ -- DefenAgeSkincare , manufacturer and distributor of revolutionary, evidence-based, anti-aging products, announces the new Defensin Master Anti-Aging Patent issued by the US Patent Office (Patent #11,491,096).
  • New patent recognizes DefenAge's ground-breaking cell stimulating compositions and methods to create fresh, new skin.
  • Seven years in the making, the new patent recognizes DefenAge's ground-breaking cell stimulating compositions and methods to create fresh, new skin.
  • The patent supports that Defensin technology is extremely effective in fighting almost any signs of skin aging and is an outstanding solution as an aging prevention treatment in both men and women.

Crown Aesthetics Announces Revolutionary Study Proving Efficacy of Patented Xycrobe® Technology

Retrieved on: 
Tuesday, November 22, 2022
Eclipse, PRP, Element, Bacteria, Health, Rejuvenation, Skin, Journal of Cosmetic Dermatology, Research, FDA, Ageing, Platelet-rich plasma, Philosophy, Doctor of Philosophy, Journal, Quality of life, Safety, Multimedia, Trial of the century, Life, Exocrine gland, Cosmetic, Symbiosis, Aesthetics, Cosmetics, Pharmaceutical industry, Dermatology, Crown

DALLAS, Nov. 22, 2022 /PRNewswire/ -- Crown Aesthetics, a Crown Laboratories, Inc. company, maintains its position at the forefront of skincare innovation with the unveiling of a new study in the Journal of Cosmetic Dermatology showcasing the efficacy of its patented Xycrobe® technology, formulated to address the often overlooked skin biome. Xycrobe technology targets certain skin conditions and cosmetic treatments using an isolated, living strain of skin-relevant bacteria. 

Key Points: 
  • DALLAS, Nov. 22, 2022 /PRNewswire/ -- Crown Aesthetics, a Crown Laboratories, Inc. company, maintains its position at the forefront of skincare innovation with the unveiling of a new study in the Journal of Cosmetic Dermatology showcasing the efficacy of its patented Xycrobe technology, formulated to address the often overlooked skin biome.
  • Xycrobe technology targets certain skin conditions and cosmetic treatments using an isolated, living strain of skin-relevant bacteria.
  • "The proven efficacy of this patented Xycrobe technology reinforces the idea that the human body depends on symbiosis.
  • Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading aesthetic practices around the world grow their businesses.

Cutera’s AviClearTM 12-Month Clinical Data Presented at the 42nd Annual Fall Clinical Dermatology Conference

Retrieved on: 
Tuesday, October 25, 2022
Cosmetics, Retail, Health, Medical Devices, Other Health, General Health, Clinical Trials, Physician, JD, MS, VP, Conference, Dermatology, Science, Journal of Cosmetic Dermatology, Patient, Research, Multimedia, Nasdaq, Medicine, Isotretinoin, Safety, Journal, Clinical trial, Laser, Acne, FDA, Solution, Pharmaceutical industry, MD

Matteo Giuseppe Scopelliti, Senior Biomedical Engineer, Cutera, Amogh Kothare, VP of Clinical and Regulatory Affairs, Cutera, and Michael Karavitis, Ph.

Key Points: 
  • Matteo Giuseppe Scopelliti, Senior Biomedical Engineer, Cutera, Amogh Kothare, VP of Clinical and Regulatory Affairs, Cutera, and Michael Karavitis, Ph.
  • Many of my patients are thrilled with their results, and with this data , we can visibly display the longstanding effectiveness of the treatment outcomes.
  • The Annual Fall Clinical Dermatology Conference has the ultimate responsibility for the planning, development and content of continuing education programs and presentations, including those highlighted above.
  • Cutera did not direct content or influence the planning or implementation of the Annual Fall Clinical Dermatology Conference.

NEW CLINICAL STUDY DEMONSTRATES COLORESCIENCE ALL CALM® REGIMEN NEUTRALIZES REDNESS AND CALMS INFLAMED SKIN

Retrieved on: 
Wednesday, June 29, 2022
Patient, Journal, Embarrassment, Journal of Cosmetic Dermatology, Skin, Trial of the century, GLOBE, Man, Social anxiety, All, Woman, Overalls, UV, CA, Health, Quality of life, Skin care, Incidence, Physician, Dermatology, Cosmetics

The 12-week open-label clinical trial assessed the efficacy and tolerability of the Colorescience All CalmSensitive Skin topical facial regimen for treating subjects with facial redness and sensitive skin.

Key Points: 
  • The 12-week open-label clinical trial assessed the efficacy and tolerability of the Colorescience All CalmSensitive Skin topical facial regimen for treating subjects with facial redness and sensitive skin.
  • As lead investigator for this study, I was able to evaluate and observe the impressive results from the All Calm Sensitive Skin Regimen.
  • The All CalmSensitive Skin Regimen products address key environmental triggers to help calm and soothe sensitive, easily irritated skin, hydrate, support skin barrier health, smooth skin texture, and provide immediate correction and ongoing relief of redness.
  • The results of this 12-week study indicate that the All Calm Sensitive Skin Regimen designed to neutralize skin redness, soothe inflamed skin, and provide sun protection was well-tolerated and improved the visible and physical symptoms of sensitive skin.

DefenAge® 10 Luxe Hand & Body Cream Wins Good Housekeeping Beauty Award for Best Anti-Aging Body Cream

Retrieved on: 
Tuesday, May 3, 2022
Cream, Hyperpigmentation, Journal of Cosmetic Dermatology, Regenerative medicine, Housekeeping, Good Housekeeping, Safety, Doctor of Philosophy, Trial of the century, Animal, Skin, Defensin, Digital firm, CEO, Research, Heart, Cell, Dermatology, Cosmetics, Pharmaceutical industry

CARLSBAD, Calif., May 3, 2022 /PRNewswire/ -- DefenAge® Skincare, the manufacturer and distributor of revolutionary, evidence-based, anti-aging products, is thrilled to announce that its new 10 Luxe Hand & Body Cream is the winner of a Good Housekeeping 2022 Beauty Award and is named Best in the 'Best-in-Class Body' category, celebrating the luxe all-over moisturizer for its breakthrough Age-Repair Defensins® technology and efficacy.

Key Points: 
  • With 19 clinical studies to support the safety and efficacy of DefenAge's formulas and Age-Repair Defensins, DefenAge 10 Luxe Hand & Body Cream withstood this rigorous testing to stand out from the competition.
  • The 10 Luxe Hand & Body Cream is specifically designed to carry the power of defensin-molecules from the neck down in a multi-functional manner.
  • The study shows that the use ofthe 10 Luxe Hand & Body Cream resulted in dramatic improvement in multiple qualities of the skin.
  • "DefenAge is beyond proud to be included in this illustrious round-up of the industry's best treatments," shares Nikolay Turovets, Ph.D., CEO of DefenAge.

Water's Edge Dermatology and Riverchase Dermatology Rebrand as AQUA Dermatology

Retrieved on: 
Tuesday, April 5, 2022
Company, GTCR, LinkedIn, Mohs surgery, Griffin, DRS, Skin, Investment, PALM, Growth, BEACH, Surgery, Business, Health care, Springfield College of Healthcare, Management & Technology, Financial services, Intracoastal Waterway, Mohs, Radiation, Dermatology, CEO, Skin cancer, Riverchase Galleria, MD, Health, O'Connell, Acquisition, Journal of Cosmetic Dermatology, AQUA, Greg Camp, California Business, Consumer Services and Housing Agency, Telecommunication, Consumer service, Physician, Founder, Acne, Technology, Patient, Partnership, Veterinary medicine, Medicine, Central Florida

PALM BEACH GARDENS, Fla., April 5, 2022 /PRNewswire/ -- Water's Edge Dermatology and Riverchase Dermatology, together a leading provider of comprehensive dermatology services in Florida and Georgia, announced today that their parent company has rebranded to AQUA Dermatology ("AQUA" or "the Company"). AQUA is owned by leading middle-market private equity firms Gryphon Investors and GTCR. The Company, with over 80 locations and more than 170 providers, was formed in 2021 through the merger of Water's Edge Dermatology and Riverchase Dermatology, and has since expanded outside of the Florida market with the June 2021 acquisition of Goodman Dermatology in Atlanta, GA.

Key Points: 
  • PALM BEACH GARDENS, Fla., April 5, 2022 /PRNewswire/ -- Water's Edge Dermatology and Riverchase Dermatology, together a leading provider of comprehensive dermatology services in Florida and Georgia, announced today that their parent company has rebranded to AQUA Dermatology ("AQUA" or "the Company").
  • Concurrently, AQUA announced that it has acquired Intracoastal Dermatology, a Jacksonville, FL-based provider of medical dermatology treatments and aesthetic skin care services.
  • Intracoastal Dermatology provides a full array of medical dermatology treatments and aesthetic skin care services in its two locations.
  • AQUA Dermatology, headquartered in Palm Beach Gardens, Florida, is among the largest and most comprehensive full-service skin care provider in the Southeast, offering Medical, Surgical and Cosmetic Dermatology.

Dr Ivan Puah Reveals That Using Calcium Hydroxyapatite Injection (Radiesse®️) Post Liposuction Can Improve Skin Laxity Significantly

Retrieved on: 
Thursday, February 24, 2022
Consensus, Hair, Abiathar, Elective surgery, Figueredo, Merz Aesthetics Women's Challenger, Cellulite, Use, Aesthetic Surgery Journal, Ministry, Merz, Buttocks, Leida Rammo, Yana, Honeycomb structure, Neck, Page, Collagen, Weight gain, Sports medicine, TCMB, Kate, Common, User experience, Medical director, Skin, Spa, Face, Lipo, Doctor of Philosophy, Lidocaine, Journal of Cosmetic Dermatology, FACS, Satō, Graduate diploma, FAAD, Allergan, DO, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Patient, Elastin, Injection, NUS, Bariatric surgery, Cosmetic, Commentary, NTU, Science, FDA, PMID, Time, Dietary supplement, Dentistry, Pharmaceutical industry, Perfume, Medical device, Abdomen, Acupuncture, Dermatology, Lorenc, Health, MD

With over 15 years of body contouring and liposuction experience, he has operated on many patients with excess body fat with pre-existing loose skin.

Key Points: 
  • With over 15 years of body contouring and liposuction experience, he has operated on many patients with excess body fat with pre-existing loose skin.
  • Dr. Puah has also co-conducted a study [8] on brachial laxity using the combination treatment of Ultherapy and Radiesse, with results demonstrating significant improvements in objective and subjective measures of brachial skin laxity.
  • MDC-Sculpt Lipo technique is a novel fat removal and body contouring technique that Dr. Ivan Puah has developed.
  • "Effectiveness of combined microfocused ultrasound with visualization and subdermal calcium hydroxyapatite injections for the management of brachial skin laxity."

Dr. Michele S. Green Continues Partnership With Exclusive Haute Beauty Network

Retrieved on: 
Thursday, February 10, 2022
Woman, Acne, News, Beauty, Rosacea, Skin, Fat removal procedures, Icahn School of Medicine at Mount Sinai, Time, Research, Skin Cancer Foundation, Hyperpigmentation, Elective surgery, Knowledge, Patient, MD, Skin cancer, Volunteering, L'Oréal, Blemish, Yale University, Genetics, Man, Haute Living, Journal of Cosmetic Dermatology, Melanoma, Johnson, Journal, Cosmetics, Medical device, Fashion, Dermatology, Roc

In addition to being a keen diagnostician and board-certified dermatologist, Dr. Green also possesses exceptional technical ability.

Key Points: 
  • In addition to being a keen diagnostician and board-certified dermatologist, Dr. Green also possesses exceptional technical ability.
  • Haute Beauty is affiliated with the luxury lifestyle publication Haute Living.
  • As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
  • For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
    Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected]

Vial announces advisory board with Dr. Leon Kircik and leading Dermatology research sites at 2022 Maui Dermatology Conference

Retrieved on: 
Monday, January 24, 2022
Journal of Cosmetic Dermatology, Research, Atopic dermatitis, Conference, Lists of people executed in the United States, SAN, Hidradenitis suppurativa, Psoriasis, Clinical trial, The Advisory Board Company, Medical director, FAAD, Rosacea, Advisory board, View, CRO, MD, Multimedia, Alopecia areata, Head, Veterinary medicine, Vitiligo, Vial, Dermatology

SAN FRANCISCO, Jan. 24, 2022 /PRNewswire/ -- Vial announces that in conjunction with the 2022 Maui Dermatology Conference it will host an Advisory Board co-hosted by Leon Kircik, MD, FAAD.

Key Points: 
  • SAN FRANCISCO, Jan. 24, 2022 /PRNewswire/ -- Vial announces that in conjunction with the 2022 Maui Dermatology Conference it will host an Advisory Board co-hosted by Leon Kircik, MD, FAAD.
  • Dr. Kircik and Vial, along with leading research sites will discuss and collaborate on how Vial can continue to help grow Dermatology research sites and tackle the biggest challenges facing Dermatology researchers today.
  • The Vial executive team is attending the 2022 Maui dermatology conference to engage with sponsors leading the forefront of Dermatology research and top research sites.
  • The Vial executive team will incorporate the Advisory Board feedback from Dermatology research sites into the Vial Dermatology strategy and release a whitepaper on the Vial.com website highlighting the feedback.

Vial launches Dermatology CRO promising Faster Execution and Higher Quality through its Network of Dermatology Clinics

Retrieved on: 
Wednesday, January 12, 2022
Journal of Cosmetic Dermatology, Research, Patient, Atopic dermatitis, SAN, Hidradenitis suppurativa, Psoriasis, Intercept Pharmaceuticals, Clinical trial, Dubois, Betsey, Medical director, Rosacea, Vial, View, Ora, CRO, Multimedia, TFS, Alopecia areata, Head, II, III, Veterinary medicine, Fine chemical, Q-Symbio, Vitiligo, Dermatology, Syneos Health

Under the tag line, "The CRO Built for Sponsors", the Vial Dermatology CRO promises higher quality and faster execution of trials powered by the Vial Clinic Network of over 35 Dermatology clinics across the country.

Key Points: 
  • Under the tag line, "The CRO Built for Sponsors", the Vial Dermatology CRO promises higher quality and faster execution of trials powered by the Vial Clinic Network of over 35 Dermatology clinics across the country.
  • The Vial Dermatology CRO team is led by Betsey Zbyszynski as Head of Clinical Operations, Jason Shuris as Head of Sales, Janet DuBois, M.D.
  • The CRO executive team joins Vial having over 100+ years of combined dermatology clinical trial experience.
  • "Vial has the technical capabilities, decades of expertise, and high-quality investigator network to be the best Dermatology CRO out there", says Justin Withers, Head of Dermatology.